Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-02-22
2001-05-22
Rotman, Alan L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S296000
Reexamination Certificate
active
06235761
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
This invention relates to 4-demethylpenclomedine, a pharmaceutical composition comprising 4-demethyl-penclomedine, and a method of using the compound in the treatment of cancer in a mammal.
BACKGROUND OF THE INVENTION
It has been estimated that approximately one out of every three Americans will develop cancer at some point during life. Currently, in spite of intensive research and some major advances in treatment, cancer claims the life of nearly one out of every four Americans.
It is indisputable, therefore, that a cure for the various types of cancer is highly needed. Several cancer chemotherapeutic drugs are known, for example, carmustine, doxorubicin, methotrexate, TAXOL®, nitrogen mustard, procarbazine, and vinblastine, to name only a few.
Many of the chemotherapeutic drugs also produce undesirable side effects in the patient. For example, U.S. Pat. No. 4,717,726 reportedly discloses a compound suitable for inhibiting the growth of certain types of malignant neoplasms in mammals. See also Plowman et al.,
Cancer Res.,
12, 1909-1915 (1989). The disclosed compound, 3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine, also known as penclomedine, is not satisfactory as a chemotherapeutic, however, because it is known to produce certain undesirable side effects especially in the central nervous system.
Neurological and hematological toxicities of penclomedine have been reported in preclinical and early clinical studies. Dose related neurotoxicity, consisting of muscle tremors, incoordination, convulsions and reduced activity, has been observed in rats. Neurotoxicity appears to be related to peak plasma drug concentrations, as it developed during or immediately after infusion and could be ameliorated by decreasing the rate of drug administration. In dogs, severe emesis and seizures have been associated with plasma penclomedine levels above 30 &mgr;M. Neurotoxicity, consisting of dysmetria, ataxia, and vertigo, was also the principal dose limiting toxicity of penclomedine administered as a one hour infusion for 5 consecutive days in patients with advanced solid tumors. The presence of these toxicities, at much lower peak plasma concentrations compared to those reported in preclinical studies, may preclude the administration of higher doses of penclomedine and the achievement of concentrations associated with optimal antitumor activity. Berlin et al.,
Proc. Amer. Assoc. Cancer Res.,
36, 238 (1995); O'Reilly et al.,
Proc. Amer. Soc. Clin. Oncol.,
14, 471 (1995).
Some relevant background art can be found in O'Reilly et al.,
Clinical Cancer Research,
2, 541-548 (March 1996). This reference describes a study to assess the distribution of
14
C-penclomedine in the tissues and tumors of tumor-bearing rats. The study found that the predominant radioactive species in the brain was
14
C-penclomedine which may explain the observed neurotoxicity of the drug.
Thus, while penclomedine has been tried as an antitumor agent, there remains a need for improved drugs that are effective in combating cancer, but at the same time produce relatively reduced side effects in the patient. An object of the invention, therefore, is to address the above need.
SUMMARY OF THE INVENTION
The present invention provides a substantially pure 3,5-dichloro-2-methoxy-4-hydroxy-6-(trichloromethyl)-pyridine or 4-demethylpenclomedine of the formula (I),
pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the aforesaid compound, and methods of using the compound in the treatment of cancer in a mammal. The compound of the present invention can be in an isolated, purified, or synthetic form.
While the invention is described and disclosed below in connection with certain preferred embodiments and procedures, it is not intended to limit the invention to those specific embodiments. Rather it is intended to cover all such alternative embodiments and modifications as fall within the spirit and scope of the claim.
REFERENCES:
patent: 4717726 (1988-01-01), Tobol
Berlin et al., “Phase I and Pharmacokinetic Trial of Penclomedine”, Proceedings of the American Association for Cancer Research Annual Meetings, 36, 389 (Mar. 1995).
Hartman et al., “Murine and Human in Vivo Penclomedine Metabolism”,Clinical Cancer Research,2 6, 953-962 (Jun. 1996).
Hartman et al., “The in Vivo Metabolism of Penclomedine (NSC 338720)”, Abstract and poster presented at the American Association for Cancer Research Annual Meeting, Canada (Mar. 1995).
O'Reilly et al., “Tissue and Tumor Distribution of 14C-Penclomedine in Rats”,Clinical Cancer Research,2 3, 541-548 (Mar. 1996).
O'Reilly et al., “Tissue and Tumor Distribution of 14C-Penclomedine and it's Metabolites in Rats With and Without Brain Tumors”, Proceedings of the American Association for Cancer Research, 36, 362 (Mar. 1995).
Plowman et al., “Preclinical Antitumor Activity of an &agr;-Picoline Derivative, Penclomedine (NSC 338720), on Human and Murine Tumors”,Cancer Research49 1909-1915 (1989).
Waud et al., “4-Demethylpenclomedine, an Antitumor-Active, Potentially Nonneurotoxic Metabolite of Penclomedine”,Cancer Research,57 5, 815-817 (Mar. 1997).
Collins Jerry M.
Hartman Neil
O'Reilly Seamus
Rowinsky Eric K.
Strong John M.
Leydig , Voit & Mayer, Ltd.
Rotman Alan L.
LandOfFree
Compound, composition and method for treating cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compound, composition and method for treating cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compound, composition and method for treating cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2562200